Astrazeneca (AZN) Revenue (2009 - 2026)

Astrazeneca's Revenue history runs 18 years deep, the most recent figure standing at $77.0 million for Q1 2026.

• In Q1 2026, Revenue rose 4.05% year-over-year to $77.0 million; the TTM figure through Mar 2026 stood at $102.0 million (down 89.29% YoY), while the FY2025 annual figure was $58.7 billion, up 6263.92% from the prior year.
• Revenue was $77.0 million for Q1 2026 at Astrazeneca, up from $6.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $815.0 million in Q4 2024 to a low of $3.0 million in Q2 2022.
• Historically, Revenue has averaged $134.7 million across 5 years, with a median of $74.0 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Revenue jumped 6333.33% in 2023, then sank 99.26% in 2025.
• A 5-year view of Revenue shows it stood at $158.0 million in 2022, then surged by 75.32% to $277.0 million in 2023, then soared by 194.22% to $815.0 million in 2024, then tumbled by 99.26% to $6.0 million in 2025, then soared by 1183.33% to $77.0 million in 2026.
• The last three Revenue figures came in at $77.0 million (Q1 2026), $6.0 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.